Hims
About Hims
Hims is a Canadian online health brand offering personalized medical consultations, prescriptions, and home delivery for men’s health needs. The service provides telehealth access to treatments for erectile dysfunction, weight loss, and acne, with nationwide shipping and discreet packaging. They emphasize at-home care with licensed providers and ongoing support, aiming to bring healthcare into the home. The Canada site highlights 2.4 million subscribers and telehealth-enabled care across the country.
Recent News
Drizzle on Top: A New High-End Dog Food Brand Is Coming for the 1%
Telehealth Provider Hims Goes After Novo's Weight Loss Pill with Compounded Version
Hims Adds Grail's Cancer Test Amid Questions About Widespread Use
Qualcomm Downgraded, Rivian Upgraded: Wall Street's Top Analyst Calls
3 Trends Shaping the GLP-1 Landscape
Photon Just Killed the “E” In E-Prescribing
FDA Chief Makary Takes Aim at Hims' Compounded Wegovy Pill Plans
Data Breaches Hit Hims & Hers and TriZetto, Exposing Millions of Patient Records
Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution
Here Are Friday's Biggest Analyst Calls: Apple, AMD, Intel, Oracle, Caterpillar, Shake Shack & More
FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide
Grail Multi-Cancer Test Taps Into Hims & Hers Network
Hers Disrupts Women’s Primary Care with Direct‑to‑Consumer Telehealth Platform
Hims Reports 2025 Earnings, Shares Details on GLP-1 Pill Decisions
STAT+: Hims’ Sales Miss as Telehealth Competition Grows
DTC Isn’t Dead
McGraw-Hill Confirms Data Breach Following Extortion Threat
The Peptide Boom Is Getting Out of Hand
GLP-1s and the Super Bowl
Hims & Hers Plans to Acquire Eucalyptus for $1.15B
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—And Big Pharma Is Paying for It
Ecommerce Trends: Which Type of Online Retailer Is Growing Fastest in the 2020s?
Telehealth Giant Hims & Hers Says Its Customer Support System Was Hacked
Celebrating, Unpacking Another Historic Week on Wall Street
Hims & Hers Stock Crashes After FDA Announces Plans to Take 'Decisive Steps' Against GLP-1 Compounds
Booking.com Breach Shows Exactly How Smishing Attacks Get Made
The Nasdaq's Win Streak, Netflix Earnings, Another AI Pivot and More in Morning Squawk
Post-Hoc Live: Analyzing the Novo Vs. Hims GLP-1 Showdown
FDA's Proposed Peptide Rule Change Boosts Hims & Hers, Sends Mixed Signals Across Pharma
China to Buy 200 Boeing Jets, Order Could Rise to 750
From Svedka to Anthropic, Brands Make Bold Plays with AI in Super Bowl Ads
The Science Behind Social Media’s Peptide Obsession
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Hims & Hers Copies Novo Nordisk's New Wegovy Pill
Novo Nordisk Signs Deal with Hims & Hers
Blackbird-Backed Telehealth Startup Eucalyptus Sells for $1.6 Billion to US Listed Rival
Eli Lilly Finds Impurity in Compounded Tirzepatide
Amazon Pharmacy Launches Same‑day Delivery of Lilly's Foundayo Weight‑loss Pill in 3,000 U.S. Cities
Stock Market Today: Nasdaq, S&P 500, Dow Fall as Wall Street Weighs CPI Inflation Print